EUCTR2010-018621-19-AT进行中（未招募）不适用
Efficacy of ALK house dust mite allergy immunotherapy tablet in subjects with house dust mite induced asthma. The MITRA Trial. - MITRA
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 800
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Male or female = 18 years.
- •A clinical relevant history consistent with HDM-induced asthma of at least 1 year prior to trial entry.
- •Use of an appropriate amount of inhaled corticosteroid (incl. combination products) in accordance with the GINA Guideline step 2-4 for the control of the asthma symptoms for a period of at least 6 months within the past year.
- •Dose of ICS after switching should at randomisation be in a range of budesonide 400-1200 mcg.
- •Documented reversible airway obstruction.
- •Asthma control level above or equal to 1.0 (asthma control questionnaire (ACQ) = 1.0) at visit 1 (screening).
- •Asthma control level between 1.0 and 1.5 (1.0 = ACQ = 1.5) at visit 3 (randomisation).
- •FEV1 = 70% of predicted value.
- •A clinical history consistent with mild to severe HDM-induced allergic rhinitis for at least 1 year.
- •Positive SPT response (wheal diameter = 3 mm larger than the negative control) to Der pte and/or Der far.
- •Positive specific IgE against Der pte and/or Der far (= IgE Class 2; = 0.70 KU/L).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 750
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 50
排除标准
- •A clinical history of persistent allergic asthma and/or rhinitis caused by an allergen to which the subject is regularly exposed and sensitized (except HDM).
- •A clinical history of intermittent allergic asthma and/or rhinitis if the seasonal allergen that may cause symptoms in the ICS reduction period (period 3).
- •Previous treatment with immunotherapy with HDM allergen for more than 1 month within the last 5 years.
- •Hospitalisation for more than 12 hours due to asthma exacerbation within the last 3 months prior to screening visit.
研究者
相似试验
进行中（未招募）
不适用
To find out if people with allergic asthma caused by house dust mites will benefit from allergy vaccine given as a tablet.House dust mite induced allergic asthmaMedDRA version: 13.1Level: LLTClassification code 10001705Term: Allergic asthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2010-018621-19-NLALK-Abelló A/S800
进行中（未招募）
不适用
To find out if people with allergic asthma caused by house dust mites will benefit from allergy vaccine given as a tablet.House dust mite induced allergic asthmaMedDRA version: 13.1Level: LLTClassification code 10001705Term: Allergic asthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2010-018621-19-DKALK-Abelló A/S800
进行中（未招募）
1 期
Efficacy of ALK house dust mite allergy immunotherapy tablet in subjects with house dust mite induced asthma. The MITRA Trial. - MITRAHouse dust mite induced allergic asthmaMedDRA version: 12.1Level: LLTClassification code 10001705Term: Allergic asthmaEUCTR2010-018621-19-SKALK-Abelló A/S800
进行中（未招募）
1 期
Efficacy of ALK house dust mite allergy immunotherapy tablet in subjects with house dust mite induced asthma. - The MITRA trial.House dust mite induced asthmaMedDRA version: 12.1 Level: LLT Classification code 10001705 Term: Allergic asthmaEUCTR2010-018621-19-GBALK-Abello A/S
进行中（未招募）
不适用
To find out if people with allergic asthma caused by house dust mites will benefit from allergy vaccine given as a tablet.House dust mite induced allergic asthmaMedDRA version: 14.0Level: LLTClassification code 10001705Term: Allergic asthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2010-018621-19-LVALK-Abelló A/S800